Chemotherapy in head and neck osteosarcoma: Adjuvant chemotherapy improves overall survival

Chen, Yiming; Gokavarapu, Sandhya; Shen, Qiang; Liu, Feng; Cao, Wei; Ling, Yue-hua; Ji, Tong

doi:10.1016/j.oraloncology.2017.08.017

Cited by 45 publications

(55 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the anatomic characteristics of the head and neck region, the surgical resection may be difficult and microscopic positive surgical margins may vary between 13 and 52% [10]. Adjuvant radiation would improve the local control in patients with adverse prognostic factors, particularly close/positive margins but its benefit in survival seems to be controversial [9,[13][14][15].…”

Section: Discussionmentioning

confidence: 99%

“…Overall and disease's free survival were significantly improved in a review of 201 patients with craniofacial OS treated with adjuvant or neoadjuvant chemotherapy [16]. Adjuvant chemotherapy improved overall survival in Chen's retrospective recent series [14]. The role of neoadjuvant chemotherapy is evolving and presently not clearly defined [13].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hyoid Bone Osteosarcoma: Report of A Case and Review of The Literature

Ayala-Ochoa¹,

Pacheco-Ojeda²,

Nicolalde-Pozo³

2019

View full text Add to dashboard Cite

Introduction: Primary lesions of the hyoid bone are exceedingly rare. This report would be the second case of a primary osteosarcoma (OS) of the hyoid bone ever reported. Case report: A 61-year old Ecuadorian woman noted an asymptomatic slowly growing mass in the upper part of neck two months before the first consultation on physical examination, a submental 6-cm, bilobulated, hard, fixed mass, extended to level IIA and the floor of the mouth, was found. Ultrasound, computed tomography and magnetic nuclear imaging reported a tumor probably originated in the hyoid bone. A wide excision, including the hypoglossal nerve, was performed, followed by eight courses of adjuvant chemotherapy, with cisplatin with doxorubicin. Pathological study revealed a high-grade conventional osteogenic sarcoma. No evidence of distant disease was found 2 years and 7 months after initial treatment. Discussion: A review of the literature was performed. Among the largest series of head and neck OS, no case of hyoid bone OS was described. Clinical presentation, imaging studies, surgical management and adjuvant radio and chemotherapy were discussed. Conclusion: A wide local excision of a hyoid bone OS and adjuvant chemotherapy allowed a survival of two and half years after treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Hyoid Bone Osteosarcoma: Report of A Case and Review of The Literature

Ayala-Ochoa¹,

Pacheco-Ojeda²,

Nicolalde-Pozo³

2019

View full text Add to dashboard Cite

show abstract

“…In previous case series, factors such as age at diagnosis, tumor size and location, pathology, presence and location of metastases, surgical strategy, surgical margins and histological responses, and acceptance of chemotherapy were reported to affect overall survival (15)(16)(17). The effect of surgical treatment of spinal osteosarcoma on overall survival is currently unclear, due to the small proportion of patients with spinal osteosarcoma.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Osteosarcoma from the spine: A population-based database study

Tang¹,

Wang

Xu³

et al. 2020

Preprint

View full text Add to dashboard Cite

PurposeThe treatment of osteosarcoma of the spine remains controversial. Our aim is to explore the treatment of patients with spinal osteosarcoma.MethodsWe analyzed the date collected 727 spinal osteosarcoma patients from the Surveillance Epidemiology and End Results (SEER) databases between 1973 and 2015. X-tile software was performed to find the optimal cut-off values of age and economic income. Univariate and Multivariate Cox analyses were used to identify the independent prognostic factors. Logistic regression model was conducted to clear the factors associated to surgical compliance; Kaplan-Meier estimator method was adopted to analyze the Overall survival (OS) and Cancer-specific survival (CSS).ResultsAmong 727 eligible spinal osteosarcoma patients, 370 (50.9%) patients received surgical treatment, 357 (49.1%) cases without surgery. There were significant differences in the effects of age at diagnosis, SEER historic stage and tumor grade on surgical treatment (All P < 0.05). Surgery was an independent prognostic factor for OS and CSS of spinal osteosarcoma patients. Spinal osteosarcoma patients undergone surgery group showed favorable survival than the other group.ConclusionsSurgery can provide survival benefits for patients with osteosarcoma of the spine. Spinal osteosarcoma patients with undergone surgery have favorable survival and surgery can become a suitable treatment for patients.

show abstract

“…In metastatic cases, clinical chemotherapy for metastatic OS is a feasible therapeutic choice. However, the drug tolerance, poor prognosis, and low survival rate occurred following the existing chemotherapy . Therefore, the substitute medication for antimetastatic OS is urgently developed prior to further clinical application.…”

Section: Introductionmentioning

confidence: 99%

“…However, the drug tolerance, poor prognosis, and low survival rate occurred following the existing chemotherapy. 5 Therefore, the substitute medication for antimetastatic OS is urgently developed prior to further clinical application. A phytoestrogen refers to a plant or herb-derived dietary estrogen as it is structural similarity with estradiol.…”

mentioning

confidence: 99%

Antimetastatic effects of calycosin on osteosarcoma and the underlying mechanism

Qiu

Qin

et al. 2019

BioFactors

View full text Add to dashboard Cite

Osteosarcoma (OS) refers to a malignant tumor with potential invasiveness and metastasis; however, the current chemotherapy of OS is lacking. Thus, the alternative drug for treating OS is urgent to explore. Calycosin (CC) is evidenced in our previous study to play the anti‐OS benefits for suppressing cancer cell proliferation. Consequently, further investigation of CC‐medicated anti‐invasive and metastatic effects against OS is needed. In the current study, the clinical samples of OS patients were collected for biological and staining assays, such as enzyme‐linked immunosorbent assay and polymerase chain reaction. Meanwhile, the cell line and tumor‐bearing nude mice were employed in assessing antimetastatic effects of CC against OS through biochemical tests and immunoassays. As a result, the OS patients exhibited upregulated neoplastic expressions of matrix metalloproteinase 2 (MMP2) and proliferating cell nuclear antigen (PCNA), cellular mRNAs and proteins of inhibitor of nuclear factor kappa‐B alpha (IκBα), and epithelial cell transforming sequence 2 (ECT2). In cell‐line study, CC‐treated human OS cells exhibited induced cell apoptosis, reduced cell proliferation, and cellular MMP2 and PCNA concentration, inhibited cell migration, lowered expressions of IκBα ECT2 mRNAs, and proteins. In tumor‐bearing nude mice study, CC‐treated mice resulted in the dose‐dependent reductions of tumor weights and intracellular MMP2 contents. As shown in further assays, neoplastic expressions of interleukin 6 protein, IκBα, ECT2 mRNAs, and proteins were downregulated dose‐dependently in CC‐treated tumor‐bearing mice. In conclusion, these investigative findings suggest that CC may play the potential anti‐invasive benefits against OS through suppressing metastasis‐associated IκBα/ECT2 molecular pathway.

show abstract

Chemotherapy in head and neck osteosarcoma: Adjuvant chemotherapy improves overall survival

Cited by 45 publications

References 26 publications

Hyoid Bone Osteosarcoma: Report of A Case and Review of The Literature

Hyoid Bone Osteosarcoma: Report of A Case and Review of The Literature

Treatment of Osteosarcoma from the spine: A population-based database study

Antimetastatic effects of calycosin on osteosarcoma and the underlying mechanism

Contact Info

Product

Resources

About